Meet us at ISPOR 2024

May 5 - 8 | Atlanta, GA

Regulatory-grade EHR data enabling scientifically rigorous research

Join Truveta in Atlanta for ISPOR 2024, where the theme is HEOR: A Transformative Force for Whole Health. Learn how Truveta can help you accelerate time to market and therapy adoption.

Join our presentation

Learn how regulatory-grade EHR data and clinical expert-led AI are unlocking novel insights and accelerating time to market.

;

See our research

Dive into four research studies highlighting findings from real-time data on GLP-1s, lecanemab for treatment of Alzheimer’s disease, and more.

;

Visit our booth

Discover how Truveta Data is the most complete, timely, and clean data for any drug, disease, or device at booth #313.

;

Meet our team

Get to know our experts and see what makes Truveta’s real-world dataset unique, including clinical notes and images.

;

Accelerating therapy adoption: the power of regulatory-grade EHR data and clinical expert-led AI

May 6, 2024 | 3:45 - 4:15pm ET

The potential of real-world data to advance research and speed therapy adoption has been recognized for some time, but fragmentation and data inaccessibility challenges have slowed progress. Truveta’s deep health system partnerships enable timely data access, and our clinical expert-led AI capabilities facilitate normalization of massive volumes of healthcare data at scale. Join presenters from Moderna and Truveta to learn how access to complete EHR data – including clinical notes – is being used to inform novel and highly-specific research on rare diseases.
Theater presentation

Ryan Ahern, MD, MPH
Chief Medical Officer & co-founder

Research posters

Real-world prescribing of Lecanemab in the United States

Presented by Tricia Rodriguez, PhD, MPH

Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023 for treatment of Alzheimer’s disease. Little is known about the uptake of the drug and the associated demographics and social drivers of health (SDOH) of patients prescribed lecanemab.

Join us to learn more about the demographics, SDOH, and uptake patterns of patients receiving lecanemab.

Descriptive statistics and disease prevalence from an electronic health record (EHR) data collective across 30+ US health systems

Presented by Sunny Guin, PhD

EHR data is often difficult to analyze at scale, given challenges harmonizing to a common data model, ensuring demographic representation and data quality, and delivering on timeliness to enable study of emerging public health trends and evolving clinical practice. Truveta confronts these challenges through a growing EHR data collective.

Join us to learn more about how Truveta assesses dataset representativeness and how disease prevalence in Truveta Data compares to government-reported and peer-reviewed resources.

Baseline A1C and BMI trends for people with type 2 diabetes receiving first-time GLP-1 RA prescriptions

Presented by Tricia Rodriguez, PhD, MPH

GLP-1 RA medications have become increasingly popular, prompting concerns about use among patients with less clinical need, which could inflate costs. Truveta Research used EHR data to investigate if pre-treatment A1c and BMI – indicators of clinical need – have changed over time for individuals with type 2 diabetes newly prescribed a GLP-1 RA.

Join us to learn more about the baseline health status of individuals newly prescribed GLP-1 RAs and explore whether this has changed over time.

Real-world prescribing of tirzepatide labeled for obesity in the United States

Presented by Tricia Rodriguez, PhD, MPH

Tirzepatide, a dual GLP-1 RA/GIP, received FDA approval as an anti-obesity medication (AOM) in November 2023 and became available in US pharmacies in December (as Zepbound). While tirzepatide labeled for obesity (AOM tirzepatide) has both a lower list price and higher placebo-controlled effectiveness than AOM semaglutide (Wegovy), insurance coverage for both AOMs remains limited, potentially restricting access.

Join us to learn more about patient characteristics and uptake for AOM tirzepatide.

May 6

12:30 - 1:30pm

Trends in first-time GLP prescribing in the US

Real-world prescribing of Lecanemab in the United States

Presented by Tricia Rodriguez, PhD, MPH

Lecanemab received accelerated FDA approval in January 2023 and full FDA approval in July 2023 for treatment of Alzheimer’s disease. Little is known about the uptake of the drug and the associated demographics and social drivers of health (SDOH) of patients prescribed lecanemab.

Join us to learn more about the demographics, SDOH, and uptake patterns of patients receiving lecanemab

May 6

4:00 - 5:00pm

Cabotegravir prescribing for HIV treatment in the US

Descriptive statistics and disease prevalence from an electronic health record (EHR) data collective across 30+ US health systems

Presented by Sunny Guin, PhD

EHR data is often difficult to analyze at scale, given challenges harmonizing to a common data model, ensuring demographic representation and data quality, and delivering on timeliness to enable study of emerging public health trends and evolving clinical practice. Truveta confronts these challenges through a growing EHR data collective.

Join us to learn more about how Truveta assesses dataset representativeness and how disease prevalence in Truveta Data compares to government-reported and peer-reviewed resources.

May 7

12:30 - 1:30pm

APOE genetic testing associated with lecanemab

Baseline A1C and BMI trends for people with type 2 diabetes receiving first-time GLP-1 RA prescriptions

Presented by Tricia Rodriguez, PhD, MPH

GLP-1 RA medications have become increasingly popular, prompting concerns about use among patients with less clinical need, which could inflate costs. Truveta Research used EHR data to investigate if pre-treatment A1c and BMI – indicators of clinical need – have changed over time for individuals with type 2 diabetes newly prescribed a GLP-1 RA.

Join us to learn more about the baseline health status of individuals newly prescribed GLP-1 RAs and explore whether this has changed over time.

May 8

9:00 - 10:00am

APOE genetic testing associated with lecanemab

Real-world prescribing of tirzepatide labeled for obesity in the United States

Presented by Tricia Rodriguez, PhD, MPH

Tirzepatide, a dual GLP-1 RA/GIP, received FDA approval as an anti-obesity medication (AOM) in November 2023 and became available in US pharmacies in December (as Zepbound). While tirzepatide labeled for obesity (AOM tirzepatide) has both a lower list price and higher placebo-controlled effectiveness than AOM semaglutide (Wegovy), insurance coverage for both AOMs remains limited, potentially restricting access.

Join us to learn more about patient characteristics and uptake for AOM tirzepatide.

Visit us at booth #313

Learn how Truveta Data, including clinical notes, is the most complete, timely, and clean data for any drug, disease, or device

Talk to our experts about what makes Truveta Data unique, how researchers are using our dataset, and how we can accelerate your organization’s research.

Join us for drinks and apps at the booth on May 6 at 5:00pm

Meet our team

Dr. Ryan Ahern Headshot

Terry Meyerson

CEO and co-founder

Terry Myerson is CEO and co-founder of Truveta, a leader in EHR data and analytics, empowering researchers to study safety and effectiveness, improve patient care, and train medical AI. Terry previously enjoyed a 21-year career at Microsoft, leading the development of Windows, Xbox, and the early days of Office 365. He’s passionate about how data, AI, healthcare, and life science innovation will save lives.

Dr. Ryan Ahern Headshot

Ryan Ahern, MD, MPH

Chief Medical Officer and co-founder

Ryan is co-founder and Chief Medical Officer of Truveta and has more than a decade of experience in healthcare data and clinical research. At Truveta, Ryan leads the Life Science Partner team which focuses on developing new partnerships and ensuring those partners are successful in their research. He is currently a Clinical Assistant Professor of Medicine at the University of Washington School of Medicine and practices at Harborview Medical Center, Seattle’s large county hospital. Prior to this, he trained in internal medicine at the Massachusetts General Hospital and has served as a Clinical Assistant Professor of Medicine at Weill Cornell Medical Center and New York Presbyterian; attending physician at Massachusetts General Hospital; and instructor at Harvard Medical School.

Conor Wyand Headshot

Betsy Wujek

VP of Biopharma Partnerships

Betsy is the Vice President of Biopharma Partnerships at Truveta. Betsy comes to Truveta with a proven track record in life sciences sales leadership and brings over 20+ years of experience to the table. Betsy is passionate about driving innovation and helping life sciences companies improve outcomes for the patients they serve. Prior to joining Truveta, Betsy spent 9 years as the Senior Vice President of Growth at Optum Life Sciences where she cultivated strong customer relationships and fostered a high-performing team. Most recently, she spent 2 years at Medidata, spearheading the launch of their innovative AI business.

Dr. Harshita Ravishankar Headshot

Harshita Ravishankar, MD, MPA

Director of Life Sciences Partnerships

Harshita is the Director of Life Sciences and Public Sector Partnerships at Truveta and brings a unique blend of medical expertise and healthcare tech experience to the role. Prior to Truveta, Harshita spent eight years with RWD/E healthcare startups including Flatiron and ConcertAI. With her passion for innovation and wealth of experience, Harshita continues to shape the future of healthcare, forging a path towards evidence-driven, patient-centric solutions. She attended medical school in India and obtained her master’s degree from NYU. She spent two years in academic research and has a background as an Emergency Medicine Physician.

Brianna Cartwright Headshot

Steve Usatine

Director of Life Sciences Partnerships

Steve is the Director of Life Sciences Partnerships at Truveta and plays a pivotal role in leveraging real-world data solutions for life sciences companies. Before joining Truveta, Steve served as a Senior Director at Clarify Health, where he spearheaded the expansion of their life sciences customer base. Over his extensive career, Steve developed his passion for improving patient health and outcomes with several pharma manufacturers promoting metabolic and rare disease therapies in specialty and hospital settings while collaborating with medical affairs and patient services teams.  

Conor Wyand Headshot

Conor Wyand

Senior Director of Life Science Solutions

Conor is the Senior Director of Life Science Solutions at Truveta where he leads a team responsible for engaging with potential new life science customers. Prior to joining Truveta in 2021, Conor spent six years in various leadership positions at Optum Life Sciences, working with pharmaceutical and medical device manufacturers across the value chain to generate RWE for therapeutics and devices. Conor graduated from Brown University with a bachelor’s degree in applied mathematics and economics. 

About ISPOR 2024

This must-attend event welcomes all healthcare stakeholders and is directly relevant to researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, healthcare providers, and patient engagement organizations. This global scientific event will cover key HEOR and RWE topics.